/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Minish Jain

George Washington University(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

114

Papers

1.4K

Citations

16

h-index

24

i10-index

Minish Jain is an academic researcher from George Washington University. The author has contributed to research in topics: Prostate Cancer Treatment and Research & HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology. The author has an h-index of 16, co-authored 97 publications.

ORCID: 0000-0002-4394-3055

Research Topics

Prostate Cancer Treatment and Research HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations Immunotherapy and Immune Responses

Papers by this author

works

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

2012 · European Journal of Cancer · 84 citations

https://doi.org/10.1016/j.ejca.2012.08.005

William J. Gradishar Virginia Kaklamani Tarini Prasad Sahoo D. Lokanatha

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

2016 · Breast Cancer Research and Treatment · 55 citations

https://doi.org/10.1007/s10549-016-3736-9

Minish Jain Smita Uday Gupte Shekhar G. Patil Anand Pathak

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

2022 · Breast Cancer Research and Treatment · 13 citations

https://doi.org/10.1007/s10549-021-06449-4

Tamas Hickish Ajay Mehta Mei-Ching Liu Chiun‐Sheng Huang

The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma

2023 · Annals of Diagnostic Pathology · 13 citations

https://doi.org/10.1016/j.anndiagpath.2023.152219

Fayez Estephan Coen J. Lap Jeff Banagan Martha Antonio

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer

2024 · Clinical Breast Cancer · 6 citations

https://doi.org/10.1016/j.clbc.2024.07.001

Rushabh Kothari Maulik Doshi P. Chaithanya Satheesh Ct

Mesenteric leiomyosarcoma in a pregnant woman: A case report and review of literature

2021 · Indian Journal of Cancer · 2 citations

https://doi.org/10.4103/ijc.ijc_705_19

SanjayP Deshmukh Minish Jain Taher Chharchhodawala

Research topics

topics

Prostate Cancer Treatment and Research

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Lung Cancer Treatments and Mutations

Immunotherapy and Immune Responses

Chat about Author

Papers

Chat

Click to start Chat